Movement Alert｜Stryker Falls 3.39% in Pre-Market Trading, Q2 Segment Revenue Miss and Multiple Price Target Cuts Weigh on Shares

Market Focus08-07 19:32

On August 7, Stryker declined 3.39% in pre-market trading, trading at $337.33/share, with turnover of $46,300. The stock continues to face selling pressure following its Q2 earnings report released on July 30.

Although Stryker reported adjusted EPS of $3.69, beating the consensus estimate of $3.49 by 5.7%, the core MedSurg and Neurotechnology segment posted sales of $3.6 billion, missing the expected $3.72 billion. Full-year adjusted EPS guidance was only marginally narrowed to $14.95-$15.10 from $14.90-$15.10 previously, disappointing investors hoping for a more meaningful raise. The stock initially plunged over 8% following the earnings release. Subsequently, multiple investment banks lowered their price targets: UBS reduced its target from $400 to $382 while maintaining a Buy rating, and Piper Sandler cut its target from $420 to $390, maintaining an Overweight rating. Rothschild & Co Redburn raised its target modestly to $360 from $346 but remains below the analyst consensus mean target of $386.44.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1131286033?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 19:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1131286033","market":"us","top_or_hot":-1,"title":"Movement Alert｜Stryker Falls 3.39% in Pre-Market Trading, Q2 Segment Revenue Miss and Multiple Price Target Cuts Weigh on Shares","media":"Market Focus","content":"<p><p>On August 7, Stryker declined 3.39% in pre-market trading, trading at $337.33/share, with turnover of $46,300. The stock continues to face selling pressure following its Q2 earnings report released on July 30.</p><p>Although Stryker reported adjusted EPS of $3.69, beating the consensus estimate of $3.49 by 5.7%, the core MedSurg and Neurotechnology segment posted sales of $3.6 billion, missing the expected $3.72 billion. Full-year adjusted EPS guidance was only marginally narrowed to $14.95-$15.10 from $14.90-$15.10 previously, disappointing investors hoping for a more meaningful raise. The stock initially plunged over 8% following the earnings release. Subsequently, multiple investment banks lowered their price targets: UBS reduced its target from $400 to $382 while maintaining a Buy rating, and Piper Sandler cut its target from $420 to $390, maintaining an Overweight rating. Rothschild & Co Redburn raised its target modestly to $360 from $346 but remains below the analyst consensus mean target of $386.44.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Stryker Falls 3.39% in Pre-Market Trading, Q2 Segment Revenue Miss and Multiple Price Target Cuts Weigh on Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Stryker Falls 3.39% in Pre-Market Trading, Q2 Segment Revenue Miss and Multiple Price Target Cuts Weigh on Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-07 19:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 7, Stryker declined 3.39% in pre-market trading, trading at $337.33/share, with turnover of $46,300. The stock continues to face selling pressure following its Q2 earnings report released on July 30.</p><p>Although Stryker reported adjusted EPS of $3.69, beating the consensus estimate of $3.49 by 5.7%, the core MedSurg and Neurotechnology segment posted sales of $3.6 billion, missing the expected $3.72 billion. Full-year adjusted EPS guidance was only marginally narrowed to $14.95-$15.10 from $14.90-$15.10 previously, disappointing investors hoping for a more meaningful raise. The stock initially plunged over 8% following the earnings release. Subsequently, multiple investment banks lowered their price targets: UBS reduced its target from $400 to $382 while maintaining a Buy rating, and Piper Sandler cut its target from $420 to $390, maintaining an Overweight rating. Rothschild & Co Redburn raised its target modestly to $360 from $346 but remains below the analyst consensus mean target of $386.44.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SYK","symbol_name":"史赛克","start_time":0,"source_url":"","article_id":"1131286033","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131286033","pubTimestamp":1786102349,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 7, Stryker declined 3.39% in pre-market trading, trading at $337.33/share, with turnover of $46,300. The stock continues to face selling pressure following its Q2 earnings report released...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SYK":"史赛克"},"translate_title":"走势警报|史赛克在盘前交易中下跌 3.39%，第二季度部门收入未达预期以及多次目标价下调给股价带来压力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SYK":1},"content_text":"On August 7, Stryker declined 3.39% in pre-market trading, trading at $337.33/share, with turnover of $46,300. The stock continues to face selling pressure following its Q2 earnings report released on July 30.Although Stryker reported adjusted EPS of $3.69, beating the consensus estimate of $3.49 by 5.7%, the core MedSurg and Neurotechnology segment posted sales of $3.6 billion, missing the expected $3.72 billion. Full-year adjusted EPS guidance was only marginally narrowed to $14.95-$15.10 from $14.90-$15.10 previously, disappointing investors hoping for a more meaningful raise. The stock initially plunged over 8% following the earnings release. Subsequently, multiple investment banks lowered their price targets: UBS reduced its target from $400 to $382 while maintaining a Buy rating, and Piper Sandler cut its target from $420 to $390, maintaining an Overweight rating. Rothschild & Co Redburn raised its target modestly to $360 from $346 but remains below the analyst consensus mean target of $386.44.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1131286033","isCrawlerRequest":true}